Evidence & regulatory context
- Mechanism
- Multi-herb traditional Dai preparation with no single defined molecular entity, so ChEMBL was NOT queried; resolved=false by modality. ClinicalTrials.gov intervention search 'Yajieshaba' returned 0 trials: an EXPLICIT NEGATIVE RESULT. No transliteration variants were tried within the time budget, so a registration under an alternative romanisation cannot be excluded.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedChemical/toxinSprague-Dawley rats; mouse strain not statedMaleOral3.51 g/kg in mice; 2.43 g/kg in rats
Model: Five acute chemical liver injury models: carbon tetrachloride, D-galactosamine, 4-acetamidophenol, thioacetamide and 1-naphthyl isothiocyanate
YJSB at 3.51 g/kg lowered serum ALT across the five injury models, most markedly for carbon tetrachloride, but did not lower AST; it prolonged sleep latency and shortened sleep time, and at 2.43 g/kg raised hepatic CYP450 and cytochrome b5 and induced CYP3A4 and CYP1A2.
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
